A Phase 3 interventional study of Letrozole and Zoledronic acid in Osteoporosis and Postmenopausal, sponsored by Novartis. Completed at 23 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-16.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Osteoporosis by Novartis — none open to participants now, none under way, none of them phase 3. Osteoporosis · Novartis.
Among the 30 studies in Osteoporosis by Novartis, this one is the 23rd largest by enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2006, is one of 18 in phase 3, and was the 13th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →None of the 30 studies in Osteoporosis by Novartis is open now. The open studies under Osteoporosis, anywhere →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is close to the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 190 across the 29 interventional studies, 1,551 across the 1 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Osteoporosis by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a prospective, randomized, open-label, two arm phase III trial designed to evaluate the efficacy and safety of zoledronic acid in preventing bone loss in postmenopausal women with operable breast cancer who had received 4 to 6 years of adjuvant tamoxifen therapy after resection of the tumor. Patients were treated with letrozole 2.5 mg orally per day or letrozole 2.5 mg orally per day in combination with zoledronic acid 4 mg/6 months as an infusion.
This trial did not recruit patients in the United States.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional protocol defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Letrozole orally 2.5 mg/day for 3 years
Drug: Letrozole
Letrozole orally 2.5mg/day for 3 years; Zoledronic acid 4mg every 6 months by infusion
Drug: Letrozole · Drug: Zoledronic acid
2.5 mg/day for 3 years
4 mg every 6 months
Change in Bone Mineral Density (BMD) From Baseline to Month 36
Change in bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) in lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.
Time frame: at 36 months as compared to baseline
Percent Change in Bone Mineral Density (BMD) From Baseline to Month 36
Bone Mineral Density is measured by dual energy x-ray absorptiometry (DXA) scan. ANCOVA model was used in the analysis where: Variable = Baseline, Center, Treatment BMD = (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.
Time frame: Baseline, Month 36
Change in T-score From Baseline to Month 36
BMD measured by DXA (dual energy x-ray absorptiometry) at lumbar spine, L1-L4. The T-Score is a comparison of a patient's BMD to that of a healthy 30 year of the same sex and ethnicity. The criteria of the World Health Organization are Normal is a T-Score of 1.0 or higher. Osteopenia is defined as between - 1.0 and -2.5. Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and half standard deviations below the mean of a 30 year old man/woman.
Time frame: Baseline and Month 36
Change in Z Score From Baseline to Month 36
Bone Mineral Density is measured by dual energy x-ray absorptiometry (DXA). The Z-Score is the number of standard deviations a patient's BMD differs from the average BMD of their age, sex and ethnicity. A Z-score of less than minus -1.5 raises concern of factors other than aging as contributing to osteoporosis.
Time frame: Baseline, month 36
Change in Bone Mineral Density From Baseline to 12 Months
Change in bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) in lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.
Time frame: Baseline, 12 months
Number of Participants With Any Kind of Fractures, by Visit.
Number of participants with fractures of any type since the last visit
Time frame: Baseline, Month 6, 12, 18, 24 , 30 and 36
Median Disease Free Survival (DFS)
Disease Free Survival is measured in days and represents the number of days participants were progression free. Progression free survival is defined as the time from randomization to the date of the first documented progression or recurrence of disease or death from any cause. Median disease free survival is the time when 50% of the patients had a recurrence.
Time frame: 36 months
Change in T-Score From Baseline to Month 12
BMD measured by DXA (dual energy x-ray absorptiometry) at lumbar spine, L1-L4. The T-Score is a comparison of a patient's BMD to that of a healthy 30 year of the same sex and ethnicity. The criteria of the World Health Organization are Normal is a T-Score of 1.0 or higher. Osteopenia is defined as between - 1.0 and -2.5. Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and half standard deviations below the mean of a 30 year old man/woman.
Time frame: Baseline, Month 12
Change in Z-Score From Baseline to Month 12
(DXA). The Z-Score is the number of standard deviations a patient's BMD differs from the average BMD of their age, sex and ethnicity. A Z-score of less than minus -1.5 raises concern of factors other than aging as contributing to osteoporosis
Time frame: Baseline, Month 12
| Milestone | Letrozole | Letrozole + Zoledronic Acid |
|---|---|---|
| Started | 40 | 41 |
| Completed | 24 | 21 |
| Not completed | 16 | 20 |
| Withdrew: Adverse event | 11 | 14 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Administrative problems | 0 | 3 |
| Withdrew: Abnormal test procedure result | 1 | 0 |
Change in bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) in lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.
| Percent | Letrozole | Letrozole + Zoledronic Acid |
|---|---|---|
| Change in Bone Mineral Density (BMD) From Baseline to Month 36 | -0.11 ± 0.14 | 0.03 ± 0.08 |
Change in bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) in lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.
| g/cm^2 | Letrozole | Letrozole + Zoledronic Acid |
|---|---|---|
| Change in Bone Mineral Density From Baseline to 12 Months | -0.04 ± 0.04 | 0.02 ± 0.05 |
Number of participants with fractures of any type since the last visit
| Participants | Letrozole | Letrozole + Zoledronic Acid |
|---|---|---|
| Baseline | 0 | 0 |
| Month 6 | 0 | 0 |
| Month 12 | 0 | 0 |
| Month 18 | 0 | 0 |
| Month 24 | 0 | 0 |
| Month 30 | 0 | 0 |
| Month 36 | 0 | 0 |
Disease Free Survival is measured in days and represents the number of days participants were progression free. Progression free survival is defined as the time from randomization to the date of the first documented progression or recurrence of disease or death from any cause. Median disease free survival is the time when 50% of the patients had a recurrence.
No measurements were reported for this outcome.
Bone Mineral Density is measured by dual energy x-ray absorptiometry (DXA) scan. ANCOVA model was used in the analysis where: Variable = Baseline, Center, Treatment BMD = (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.
| Percent Change in BMD | Letrozole | Letrozole + Zoledronic Acid |
|---|---|---|
| Percent Change in Bone Mineral Density (BMD) From Baseline to Month 36 | -11.34 ± 17.72 | 3.31 ± 8.32 |
BMD measured by DXA (dual energy x-ray absorptiometry) at lumbar spine, L1-L4. The T-Score is a comparison of a patient's BMD to that of a healthy 30 year of the same sex and ethnicity. The criteria of the World Health Organization are Normal is a T-Score of 1.0 or higher. Osteopenia is defined as between - 1.0 and -2.5. Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and half standard deviations below the mean of a 30 year old man/woman.
| T-Score | Letrozole | Letrozole + Zoledronic Acid |
|---|---|---|
| Change in T-score From Baseline to Month 36 | -0.90 ± 1.03 | 0.46 ± 0.27 |
Bone Mineral Density is measured by dual energy x-ray absorptiometry (DXA). The Z-Score is the number of standard deviations a patient's BMD differs from the average BMD of their age, sex and ethnicity. A Z-score of less than minus -1.5 raises concern of factors other than aging as contributing to osteoporosis.
| Z-Score | Letrozole | Letrozole + Zoledronic Acid |
|---|---|---|
| Change in Z Score From Baseline to Month 36 | -0.31 ± 0.35 | 0.25 ± 0.34 |
BMD measured by DXA (dual energy x-ray absorptiometry) at lumbar spine, L1-L4. The T-Score is a comparison of a patient's BMD to that of a healthy 30 year of the same sex and ethnicity. The criteria of the World Health Organization are Normal is a T-Score of 1.0 or higher. Osteopenia is defined as between - 1.0 and -2.5. Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and half standard deviations below the mean of a 30 year old man/woman.
| T-Score | Letrozole | Letrozole + Zoledronic Acid |
|---|---|---|
| Change in T-Score From Baseline to Month 12 | -0.31 ± 0.35 | 0.25 ± 0.34 |
(DXA). The Z-Score is the number of standard deviations a patient's BMD differs from the average BMD of their age, sex and ethnicity. A Z-score of less than minus -1.5 raises concern of factors other than aging as contributing to osteoporosis
| Z-Score | Letrozole | Letrozole + Zoledronic Acid |
|---|---|---|
| Change in Z-Score From Baseline to Month 12 | -0.26 ± 0.35 | 0.37 ± 0.38 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Letrozole | — | 6/40 (15%) | 35/40 (87.5%) |
| Letrozole + Zolendronic Acid | — | 7/41 (17.1%) | 35/41 (85.4%) |
| Event | Letrozole | Letrozole + Zolendronic Acid |
|---|---|---|
| VERTIGO POSITIONALEar and labyrinth disorders | 1/40 | 0/41 |
| CONCOMITANT DISEASE PROGRESSIONGeneral disorders | 1/40 | 0/41 |
| CHOLECYSTITISHepatobiliary disorders | 1/40 | 0/41 |
| FALLInjury, poisoning and procedural complications | 1/40 | 0/41 |
| LOWER LIMB FRACTUREInjury, poisoning and procedural complications | 1/40 | 0/41 |
| AXILLARY MASSMusculoskeletal and connective tissue disorders | 1/40 | 0/41 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 1/40 | 1/41 |
| METASTASES TO BONENeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/40 | 0/41 |
| METASTASES TO LIVERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/40 | 0/41 |
| METASTASES TO LUNGNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/40 | 0/41 |
| Event | Letrozole | Letrozole + Zolendronic Acid |
|---|---|---|
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 11/40 | 14/41 |
| BONE PAINMusculoskeletal and connective tissue disorders | 12/40 | 14/41 |
| FATIGUEGeneral disorders | 2/40 | 12/41 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 5/40 | 10/41 |
| HOT FLUSHVascular disorders | 9/40 | 9/41 |
| PYREXIAGeneral disorders | 0/40 | 9/41 |
| HEADACHENervous system disorders | 5/40 | 9/41 |
| NAUSEAGastrointestinal disorders | 0/40 | 7/41 |
| CHILLSGeneral disorders | 1/40 | 7/41 |
| ALOPECIASkin and subcutaneous tissue disorders | 6/40 | 6/41 |
| Age, Categorical(Participants) | Letrozole | Letrozole + Zoledronic Acid | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 37 | 39 | 76 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Letrozole | Letrozole + Zoledronic Acid | Total |
|---|---|---|---|
| Mean | 61.3 ± 7.3 | 58.4 ± 7.3 | 59.8 ± 7.4 |
| Sex: Female, Male(Participants) | Letrozole | Letrozole + Zoledronic Acid | Total |
|---|---|---|---|
| Female | 37 | 39 | 76 |
| Male | 0 | 0 | 0 |
The record gives a start of Jan 2006, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letrozole